Premium
Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines
Author(s) -
Ando Takashi,
Ichikawa Jiro,
Okamoto Atsushi,
Tasaka Kachio,
Nakao Atsuhito,
Hamada Yoshiki
Publication year - 2005
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1016/j.orthres.2005.01.010
Subject(s) - gemcitabine , osteosarcoma , apoptosis , cancer research , cell culture , in vivo , dna fragmentation , metastasis , viability assay , medicine , pathology , chemistry , biology , chemotherapy , cancer , programmed cell death , biochemistry , microbiology and biotechnology , genetics
Gemcitabine (dFdCyd) is an analog of cytosine arabinoside with anti‐tumor activity in several human cancers. However, the efficacy of this compound in osteosarcoma has not been fully elucidated. Here we assessed the anti‐tumor activity of gemcitabine using osteosarcome cell lines. In 9 human osteosarcoma cell lines (G292, HOS, MG63, NY, SaOS, HuO, HuO‐3N1, HuO9, HuO9‐N2), gemcitabine at the doses of > 100 nM showed significant cytotoxicity. In HOS and MG63 cell lines, gemcitabine inhibited DNA synthesis as determined by IdU labeling assay and induced apoptosis as determined by DNA fragmentation assay and May‐Giemsa staining. In C3H mice inoculated s.c. with a murine osteosarcoma cell line, LM8, treatment of the mice with gemcitabine showed reduced size of the primary tumor associated with increased apoptotic cells and a virtual absence of metastatic lesions in the lung. Gemcitabine thus had anti‐tumor activity on osteosarcoma cell lines both in vitro and in vivo. The result would provide a cellular basis for application of gemcitabine to patients with osteosarcoma. © 2005 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved.